Tolmar Pharmaceuticals Sponsors 2018 ZERO - The End of Prostate Cancer Endurance Team at the Bank of America Chicago Marathon
CHICAGO and BOSTON, Oct. 5, 2018 /PRNewswire/ -- Tolmar Pharmaceuticals, Inc. today announced its exclusive sponsorship of ZERO - The End of Prostate Cancer's (ZERO) Endurance Team at the 2018 Bank of America Chicago Marathon. ZERO is the leading national nonprofit organization dedicated to advancing research, grass roots advocacy, education and support programs for patients with prostate cancer. Tolmar employees from across the country will run the marathon on October 7, 2018 to raise prostate-cancer awareness and support as part of Team ZERO.
"We are proud to sponsor Team ZERO at this year's Bank of America Chicago Marathon as a natural extension of our multi-year partnership, which supports their Run/Walk Series nationwide," said Susan Rodriguez, CEO, Tolmar Pharmaceuticals. "With our commercial offices based in the Chicago area, it is especially exciting to play our part in raising awareness by participating in the marathon."
Ms. Rodriguez continued, "We take great pride in our hands-on engagement with the advanced prostate cancer community. As a company with a product line dedicated to advanced prostate cancer patients, our passion for what we do is exemplified by our many employees who participate themselves in the run/walks organized by ZERO across the country."
Tolmar's support for ZERO's Run/Walk series in 2018 brings local communities together with prostate cancer care providers, patients and family members across events planned for 42 cities across the U.S.
"The enthusiastic support we receive from Tolmar and our other partners is critical to achieving our ultimate goal to end prostate cancer," said Jamie Bearse, President and CEO, ZERO – The End of Prostate Cancer. "It's incredibly gratifying to see so many of our collaborators and colleagues join us on race days, unified in our mission and in support of patients, their families and loved ones."
About ZERO – The End of Prostate Cancer
ZERO — The End of Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer. ZERO advances research, improves the lives of men and families, and inspires action. We're building Generation ZERO, the first generation of men free from prostate cancer, through our national run/walk series, education and patient support programs, and grassroots advocacy. ZERO is a 501(c)(3) philanthropic organization recognized with four out of four stars by Charity Navigator, accredited by the Better Business Bureau, with regional chapters across the country. We dedicate 85 cents of every dollar to research and programs. For more information, visit www.zerocancer.org.
About Tolmar and ELIGARD (leuprolide acetate for injectable suspension)
Tolmar Pharmaceuticals, Inc., along with its affiliated companies, is a fully integrated pharmaceutical company focused on the innovative development, approval, manufacturing and commercialization of specialty pharmaceuticals. The Company's lead product, ELIGARD® (leuprolide acetate for injectable suspension), is a gonadotropin releasing hormone (GnRH) agonist indicated for the palliative treatment of advanced prostate cancer. Tolmar global headquarters, product development and manufacturing facilities are based in northern Colorado, while Tolmar Pharmaceuticals' U.S. commercial business is based in Lincolnshire, Illinois. For more information about the company, please visit www.Tolmar.com. Information about ELIGARD is available at www.eligard.com.
ELIGARD (leuprolide acetate for injectable suspension) is a prescription drug, given by injection, for the management of advanced prostate cancer. However, there is no known cure for advanced prostate cancer.
Important Safety Information for ELIGARD (leuprolide acetate for injectable suspension)
ELIGARD® is a medicine for the treatment of advanced prostate cancer. It works by reducing the amount of testosterone in the blood. It is not a cure.
ELIGARD should not be used by anyone who is allergic to any of the ingredients in ELIGARD or to any medicines that reduce testosterone the same way. ELIGARD should not be used by women who are pregnant or may become pregnant. ELIGARD can cause pregnancy loss or harm to an unborn baby if used in pregnant women.
Severe and possibly life-threatening reactions called anaphylaxis have occurred in people receiving ELIGARD.
Increased risk of heart attack, sudden death due to heart problems and stroke have also been reported in men taking ELIGARD. ELIGARD may also affect electrical activity in the heart that can cause an irregular heartbeat. Your doctor will monitor you for heart conditions.
Elevated blood sugar and an increased risk of developing diabetes have been reported in men receiving ELIGARD. Your doctor will monitor blood sugar levels.
ELIGARD causes an increase in testosterone during the first few weeks of therapy and some men may experience new or worsening symptoms of prostate cancer e.g., bone pain, urinary symptoms, or nerve problems such as numbness, during this period. If your cancer has spread to the urinary tract or spine, urinary blockage or pressure on the spine that can lead to paralysis may occur. Your doctor will discuss with you the benefits and risks of taking ELIGARD.
The most common injection site reactions are transient burning and stinging, pain, bruising, and redness. The most common side effects include hot flashes/sweats, fatigue, weakness, muscle pain, dizziness, clamminess, testicular shrinkage, decreased erections and enlargement of breasts. Other side effects, including thinning of bones that may lead to fracture, and rare but serious problems with the pituitary gland in the brain, have been reported with ELIGARD.
See package insert for full prescribing and safety information.
SOURCE Tolmar Pharmaceuticals, Inc.
Share this article